1. Norway Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Thor Medical ASA

Thor Medical ASA

4.36
NOK
-0.10
(-2.35%)
-4.01EPS
Mar 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.01
0.02
0.01
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.71
-2.28
-4.07
-5.01
-5.7
-6.56
-7.26
-5.77
-4.53
-2.63
-0.15
-0.18
-0.17
-4.01
Free Cash Flow per Basic Share
-0.61
-2.14
-3.59
-4.37
-4.89
-6.39
-6.89
-5.51
-4.15
-3.51
-0.37
-0.1
-0.36
-3.63
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.29
11.84
15.24
18.45
13.19
6.99
5.6
2.15
1.38
0.54
1.13
1.2
1.29
1.53
Tangible Book Value per Share
3.29
11.82
15.23
18.45
13.19
6.99
5.6
2.15
1.38
0.54
-0.05
0.19
0.54
1.53
Basic Weighted Avg Shares
24
28
42
47
52
51
60
72
97
118
175
236
332
108
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-5,917.48
-15,642.37
-41,898.17
-68,905.1
-104,808.61
- -
- -
- -
- -
- -
- -
- -
-15,866.51
- -
Depreciation Expense
- -
- -
1
1
1
2
13
15
11
11
1
2
21
10
Net Income, GAAP
-17
-64
-173
-236
-294
-338
-434
-417
-441
-311
-27
-42
-58
-434
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-5,558.02
-14,504.1
-39,605.26
-75,003.18
-97,289.4
- -
- -
- -
- -
- -
- -
- -
-13,214.58
- -
Working Capital
78
329
710
946
679
362
376
180
139
65
41
107
156
186
LT Debt
- -
- -
- -
- -
- -
- -
5
2
- -
- -
- -
- -
159
- -
Total Equity
79
330
713
949
680
363
388
179
141
64
272
337
456
183
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-39.35
-31.14
-33.19
-28.34
-36.08
-64.78
-115.44
-147.2
-276.52
-304.6
-15.82
-13.86
-14.63
-155.9

Capital Structure

NOK

•

in mil. unless spec.
Dec'21
Mar'22
Jun'22
ST Debt
6
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
102
119
119
Market Capitalization
- -
- -
- -

Working Capital

NOK

•

in mil. unless spec.
Dec'21
Mar'22
Jun'22
Total Current Assets
291
376
310
Cash, Cash Equivalents & STI
277
356
287
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
152
104
124
Payables & Accruals
- -
- -
- -
ST Debt
6
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

NOK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.03%
61.85%
35.25%
Free Cash Flow
36.72%
51.47%
400.22%
Net Income, GAAP
8.16%
-3.76%
37.44%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

NOK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

NOK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.18
2025
- -
- -
-0.17
2026
- -
- -
- -

Semi-annual Dividends Per Share

NOK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jasper Kurth
Full Time Employees
18
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Drammensveien 167 Oslo PS Norway 0277
IPO Date
Jul 7, 2014
Website
thormedical.com
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Thor Medical ASA, a Norway-based biotechnology company founded in 2017 and headquartered in Oslo, produces and supplies alpha-particle emitters for targeted cancer therapies using a proprietary process that separates naturally occurring radioactive decay products from thorium-232 (Th-232); its core products include thorium-228 (Th-228) as a precursor for lead-212 (Pb-212), radium-224 (Ra-224), and related alpha-emitting isotopes that enable radionuclide therapy (RNT) and radioligand therapy (RLT) with high energy deposition, short range, and minimal damage to healthy tissue. The company targets radiopharmaceutical developers and suppliers addressing unmet needs in oncology, including hard-to-treat solid tumors and hematological cancers such as lymphoma, leukemia, and metastasized prostate cancer; it operates primarily from Norway with its AlphaOne commercial-scale production facility under construction at Herøya Industripark, slated to commence thorium-based isotope output in the third quarter of 2026. Formerly known as Nordic Nanovector ASA, Thor Medical has pursued strategic growth through recent five-year supply agreements for Th-228, including partnerships with global radiopharmaceutical leader Telix Pharmaceuticals Limited in November 2025 to support Pb-212-based next-generation therapies and with NucliThera AS in November 2025 for hematological cancer programs led by veterans of FDA-approved alpha-emitter Xofigo; these deals expand its customer portfolio alongside prior commitments from Oncoinvent, AdvanCell, ARTBIO, and others, while pilot facilities established at Herøya in 2024 enable customer sample qualification and conversion of letters of intent into binding contracts.